Jump to content
Sclero Forums

Search the Community

Showing results for tags 'selexipag'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 2 results

  1. Selexipag for the treatment of connective tissue disease–associated pulmonary arterial hypertension (PAH). Selexipag delayed progression of PAH and was well–tolerated among PAH–Connective Tissue Disease patients, including those with PAH–Scleroderma and PAH–Systemic Lupus Erythematosus. PubMed, Eur Respir J, 2017 Aug 17;50(2). (Also see Uptravi® (Selexipag) for Pulmonary Hypertension) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Uptravi® (Selexipag) for Pulmonary Hypertension. Uptravi® (selexipag) is an oral IP prostacyclin receptor agonist marketed by Actelion Pharmaceuticals US, Inc., which was approved by the US FDA for the treatment of pulmonary arterial hypertension in December 2015. Posted 01/29/2016. This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...